NRx Pharmaceuticals, Inc. (NRXP)Healthcare | Biotechnology | Wilmington, United States | NasdaqCM
2.71 USD
+0.12
(4.633%)
⇧
(Oct. 15, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | Oct. 10, 2026, 3:46 a.m. EDT
The investment case here is a binary gamble on a biotech turnaround, not a traditional value play. Fundamentally, the company is in distress with negative earnings, negative free cash flow, and a balance sheet showing negative book value. The multi-year price trajectory is catastrophic, having lost nearly 97% of its value over the last seven years, indicating the market has permanently repriced the business quality despite a recent single-year recovery. There is no dividend to provide income, and the valuation metrics are distorted by losses. However, the short-term outlook is driven entirely by speculative positioning rather than immediate catalysts. The options chain reveals a heavy concentration of call buyers betting on a significant move higher, specifically targeting the $5.00 level. This creates a high-risk, high-reward scenario where the stock could surge on news or technical momentum, but the lack of put protection means there is no downside buffer for bulls. The statistical forecasting models are useless here due to extreme volatility and low reliability scores. In summary, this is a speculative vehicle for traders willing to risk total capital loss for a chance at a multiple-bagger based on clinical trial results or a successful public offering, rather than a stable investment for wealth preservation or steady growth. |
| Model | MAE |
|---|---|
| AutoARIMA ✓ | 0.199054 |
| AutoETS | 0.199056 |
| MSTL | 0.207175 |
| AutoTheta | 0.245711 |
Forecast horizon: 45 days | Selected: AutoARIMA
| Forecast Reliability | |
|---|---|
| Score | 29% |
| H-stat | 0.92 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.000 |
| Excess Kurtosis | 3.60 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Revenue per Share | 0.112 |
| Market Cap | 117,331,536 |
| Forward P/E | -7.74 |
| Beta | 2.07 |
| Previous Name | NeuroRx, Inc. |
| Website | https://www.nrxpharma.com |
As of Oct. 10, 2026, 3:46 a.m. EDT: Speculators are overwhelmingly positioning for a rally, with massive open interest in out-of-the-money calls at the $5.00 strike compared to negligible put activity. This creates a distinct gamma squeeze environment where any upward price movement could trigger cascading call buying, though the lack of protective puts suggests a 'naked' bullish bet rather than a hedged strategy.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.14779872 |
| Address1 | 1,201 N. Market Street |
| Address2 | Suite 111 |
| All Time High | 769.9 |
| All Time Low | 1.1 |
| Ask | 3.44 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 595,020 |
| Average Daily Volume3 Month | 848,018 |
| Average Volume | 848,018 |
| Average Volume10Days | 595,020 |
| Beta | 2.074 |
| Bid | 2.7 |
| Bid Size | 1 |
| Book Value | -0.004 |
| City | Wilmington |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 2.71 |
| Current Ratio | 0.861 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,790,726,400 |
| Day High | 2.7718 |
| Day Low | 2.48 |
| Display Name | NRx Pharmaceuticals |
| Dividend Yield | 0.0 |
| Earnings Call Timestamp End | 1,786,996,800 |
| Earnings Call Timestamp Start | 1,786,996,800 |
| Earnings Timestamp End | 1,794,513,600 |
| Earnings Timestamp Start | 1,794,513,600 |
| Ebitda | -19,762,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -4.625 |
| Enterprise To Revenue | 26.927 |
| Enterprise Value | 91,390,384 |
| Eps Current Year | -0.8 |
| Eps Forward | -0.35 |
| Eps Trailing Twelve Months | -0.55 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 15 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.2372 |
| Fifty Day Average Change | -0.5272 |
| Fifty Day Average Change Percent | -0.16285679 |
| Fifty Two Week Change Percent | -14.779872 |
| Fifty Two Week High | 5.055 |
| Fifty Two Week High Change | -2.3449998 |
| Fifty Two Week High Change Percent | -0.4638971 |
| Fifty Two Week Low | 1.62 |
| Fifty Two Week Low Change | 1.09 |
| Fifty Two Week Low Change Percent | 0.6728395 |
| Fifty Two Week Range | 1.62 - 5.055 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,512,397,800,000 |
| Float Shares | 37,388,639 |
| Forward Eps | -0.35 |
| Forward P E | -7.7428575 |
| Free Cashflow | -9,639,625 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 29 |
| Fullday Change | 0.029500008 |
| Fullday Change Percent | 1.0885612 |
| Fullday Price | 2.7395 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.46640998 |
| Gross Profits | 1,583,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.04117 |
| Held Percent Institutions | 0.27126 |
| Implied Shares Outstanding | 43,295,767 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,712,016,000 |
| Last Split Factor | 1:10 |
| Long Business Summary | NRx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder (PTSD), and schizophrenia in the United States. It operates through NRx and Dura segments. The company develops NRX-101, an oral fixed-dose combination of D-cycloserine (DCS) and lurasidone in Phase 2/3 clinical testing for bipolar depression with sub-acute ideation and behavior; NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression; and KETAFREE, a generic preservative-free formulation of ketamine. It also provides precision-based interventional psychiatry services to patients with treatment-resistant depression and PTSD using a combination of neuroplastic drugs, transcranial magnetic stimulation (TMS), digital therapeutics, and hyperbaric therapy; ketamine infusion therapy; stellate ganglion blocks; Spravato administration; psychotherapy; and medication management. The company has a development and license agreement with Glytech LLC. NRx Pharmaceuticals, Inc. was founded in 2015 and is headquartered in Wilmington, Delaware. |
| Long Name | NRx Pharmaceuticals, Inc. |
| Market | us_market |
| Market Cap | 117,331,536 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_319388181 |
| Most Recent Quarter | 1,782,777,600 |
| Name Change Date | 2,026-10-16 |
| Net Income To Common | -23,480,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 136,814,623 |
| Number Of Analyst Opinions | 4 |
| Open | 2.53 |
| Operating Cashflow | -19,774,000 |
| Operating Margins | -5.90463 |
| Phone | 484 254 6134 |
| Pre Market Change | 0.029500008 |
| Pre Market Change Percent | 1.0885612 |
| Pre Market Price | 2.7395 |
| Pre Market Time | 1,792,149,724 |
| Prev Name | NeuroRx, Inc. |
| Previous Close | 2.59 |
| Price Eps Current Year | -3.3875 |
| Price Hint | 4 |
| Price To Book | -677.5 |
| Price To Sales Trailing12 Months | 34.570282 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.794 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.12 |
| Regular Market Change Percent | 4.63321 |
| Regular Market Day High | 2.7718 |
| Regular Market Day Low | 2.48 |
| Regular Market Day Range | 2.48 - 2.7718 |
| Regular Market Open | 2.53 |
| Regular Market Previous Close | 2.59 |
| Regular Market Price | 2.71 |
| Regular Market Time | 1,792,094,400 |
| Regular Market Volume | 1,177,417 |
| Return On Assets | -0.6399 |
| Revenue Per Share | 0.112 |
| Sand P52 Week Change | 0.16207206 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 43,295,767 |
| Shares Percent Shares Out | 0.22620001 |
| Shares Short | 9,793,940 |
| Shares Short Previous Month Date | 1,788,134,400 |
| Shares Short Prior Month | 9,296,173 |
| Short Name | NRX Pharmaceuticals, Inc. |
| Short Percent Of Float | 0.2359 |
| Short Ratio | 15.1 |
| Source Interval | 15 |
| State | DE |
| Symbol | NRXP |
| Target High Price | 50.0 |
| Target Low Price | 10.0 |
| Target Mean Price | 38.5 |
| Target Median Price | 47.0 |
| Total Cash | 26,686,000 |
| Total Cash Per Share | 0.617 |
| Total Debt | 834,000 |
| Total Revenue | 3,394,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.55 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 2.9581 |
| Two Hundred Day Average Change | -0.24810004 |
| Two Hundred Day Average Change Percent | -0.08387142 |
| Type Disp | Equity |
| Volume | 1,177,417 |
| Website | https://www.nrxpharma.com |
| Zip | 19,801 |